Phoebe Sedgman
Editor at Bloomberg News
Editor at @business, looking at consumer goods, casinos and coronavirus. Plus planes, trains and automobiles. Retweets aren't endorsements. Likes = bookmarks
Articles
-
4 days ago |
rs.bloombergadria.com | Phoebe Sedgman
Podeli vest WhatsApp Viber Link copied Copy link Kompanije 02. jun 2025, 19:00 Sanofi je pristao da kupi kompaniju Blueprint Medicines Corp. za najmanje 9,1 milijardu dolara, i ovim francuski proizvođač lekova dodatno širi svoje prisustvo u oblasti retkih imunoloških bolesti. Sanofi će platiti 129 dolara po akciji u gotovini za američku biotehnološku firmu, navodi se u saopštenju.
-
4 days ago |
news.bloomberglaw.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong
Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday. The pharmaceutical firm has touted its ambition to become an immunology powerhouse, and earlier this year it clinched a pact to buy a promising antibody drug for up to $1.9 billion.
-
4 days ago |
bloomberglinea.com.br | Phoebe Sedgman |Amber Tong |Ashleigh Furlong |Seong Joon Cho
Bloomberg — A Sanofi concordou em comprar a Blueprint por pelo menos US$ 9,1 bilhões, à medida que a farmacêutica francesa se expande ainda mais em doenças imunológicas raras. A Sanofi pagará US$ 129 por ação pela biotecnologia americana, informou em um comunicado. Isso representa um prêmio de 27% sobre o preço de fechamento da Blueprint na sexta-feira.
-
4 days ago |
news.bloombergtax.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong
Sanofi SA agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker further expands its rare immunological disease portfolio. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday. Sanofi has touted its ambition to become an immunology powerhouse, and earlier this year it clinched a pact to buy a promising antibody drug for up to $1.9 billion.
-
4 days ago |
bloomberg.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong
Laboratory research. Photographer: SeongJoon Cho/Bloomberg(Bloomberg) -- Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 835
- Tweets
- 4K
- DMs Open
- No
When Kenny Ives took over as boss of the trading arm of one of China’s top miners, his model was clear: “23 years at Glencore, and I loved it. So why would I do it differently?” https://t.co/xBd90AAe9J
https://t.co/jITHlZs9U8
RT @crampell: Ozempic & Wegovy are tilting scales of Denmark’s economy Danish drugmaker’s US sales have been so strong it's had to convert…